- |||||||||| IOS-1002 / ImmunOs Therap
Journal: IOS-1002, a Stabilized HLA-B57 Open Format, Exerts Potent Anti-Tumor Activity. (Pubmed Central) - Aug 31, 2024 Lastly, IOS-1002 demonstrates efficacy in an ex vivo patient-derived tumor sample tumoroid model. IOS-1002 is a first-in-class multi-target and multi-functional human-derived HLA molecule that activates anti-tumor immunity and is currently under clinical evaluation.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adverse events, Real-world evidence, Real-world: Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study. (Pubmed Central) - Aug 31, 2024 This study demonstrates that the use of CDK4/6 inhibitors is associated with cardiovascular adverse events, such as heart failure and hypertension. Further research is needed to understand the mechanisms and risk factors contributing to the cardiovascular toxicity of CDK4/6 inhibitors.
- |||||||||| Journal, Adverse events, Checkpoint inhibition: Co-Occurring Infections in Cancer Patients Treated with Checkpoint Inhibitors Significantly Increase the Risk of Immune-Related Adverse Events. (Pubmed Central) - Aug 31, 2024
Reports concerning pembrolizumab, nivolumab, cemiplimab, avelumab, durvalumab, atezolizumab, and ipilimumab revealed a statistically significant association between the irAEs and concurrent infectious diseases for five out of seven treatments. Furthermore, the association trend was preserved across all three types of checkpoint inhibitors and each of the five individual therapeutic agent cohorts, while the remaining two showed the same trend, but an increased confidence interval, due to an insufficient number of records.
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Retrospective data, Review, Journal, Metastases: Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis. (Pubmed Central) - Aug 31, 2024 Furthermore, the association trend was preserved across all three types of checkpoint inhibitors and each of the five individual therapeutic agent cohorts, while the remaining two showed the same trend, but an increased confidence interval, due to an insufficient number of records. Sorafenib or lenvatinib can provide effective treatment with manageable toxicity in patients with advanced HCC after disease progression under atezolizumab-bevacizumab.
- |||||||||| sunitinib / Generic mfg.
Journal, Metastases: Predicting Survival of Metastatic Clear Cell Renal Cell Cancer Treated with VEGFR-TKI-Based Sequential Therapy. (Pubmed Central) - Aug 31, 2024 (2) A prospectively maintained database of 145 patients with mRCC treated between 2008 and 2018 was analyzed to predict the CSS of patients receiving sunitinib and second- and third-line therapies according to current standards of practice...(4) A nomogram to predict CSS in patients with CC mRCC that incorporates patient status, clinical risk classification and response criteria to first-line VEGFR-TKI at 3 months is presented. This new tool may be useful to clinicians assessing the risk and prognosis of patients with mRCC.
- |||||||||| Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, Checkpoint block: Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies. (Pubmed Central) - Aug 31, 2024
Osimertinib and alectinib, both TKIs, have shown significant improvements in outcomes for patients with resected EGFR- and ALK-positive NSCLC, respectively, changing the standard of care in these subgroups...In addition, several ICBs have been tested and approved as adjuvant (atezolizumab and pembrolizumab), neoadjuvant (nivolumab), and perioperative treatments (pembrolizumab) for patients with resectable early-stage NSCLC...Furthermore, potential predictive biomarkers for efficacy are needed to eventually intensify the entire perioperative strategies. This review aims to summarize and discuss the available evidence, the ongoing trials, and the challenges associated with TKI- and ICB-based approaches in early-stage NSCLC.
- |||||||||| sunitinib / Generic mfg.
Biomarker, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Multifaceted role of FAM210B in hepatocellular carcinoma: Implications for tumour progression, microenvironment modulation and therapeutic selection. (Pubmed Central) - Aug 31, 2024 High expression levels of FAM202B correlated with increased resistance to sunitinib and enhanced responsiveness to immunotherapy, as evidenced by associations with tumour mutation burden, PDCD1, CTLA4 and TIDE scores. FAM210B exerts a complex influence on HCC, affecting tumour cell behaviour, metabolic pathways, the immune microenvironment and responses to therapy.
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal: EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors. (Pubmed Central) - Aug 31, 2024 Finally, we identify candidate EWS-WT1 target genes with potential therapeutic implications, including CCND1, whose inhibition by the clinically-approved drug Palbociclib leads to marked tumor burden decrease in DSRCT PDXs in vivo. Taken together, our studies identify gene regulation programs and therapeutic vulnerabilities in DSRCT and provide a mechanistic understanding of the complex oncogenic activity of EWS-WT1.
- |||||||||| Review, Journal: Novel antibody-drug conjugates based on DXd-ADC technology. (Pubmed Central) - Aug 31, 2024
This review provides a comprehensive assessment of drugs developed with DXd-ADC technology, with a focus on mechanisms of action, pharmacokinetics studies, preclinical data, and clinical outcomes for DS-8201a, U3-1402, DS-1062a, DS-7300a, DS-6157a, and DS-6000a. By integrating existing data, we aim to provide valuable insights into the current therapeutic status and future prospects of these novel agents.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Journal: Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021. (Pubmed Central) - Aug 31, 2024 We divided the total number of monthly prescriptions by 12 or 2 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates...In line with global trends, MS prevalence is escalating in Australia, particularly in higher-latitude states. MS prevention is crucial to halt this disturbing trend.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Review, Journal, Checkpoint inhibition, Checkpoint block: The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases. (Pubmed Central) - Aug 31, 2024 Two prospective phase 2 trials evaluating pembrolizumab monotherapy and atezolizumab plus CT in patients with untreated NSCLC BM also demonstrated significant intracranial responses. This review describes the interplay between CNS immune cells and tumor cells, discusses current evidence for ICI CNS activity from retrospective and prospective studies, and speculates on future directions of investigation.
- |||||||||| Bexxar (iodine I 131 tositumomab) / GSK, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Review, Journal: Radioligand Therapy in Lymphoma: Past, Present, and Future. (Pubmed Central) - Aug 31, 2024 This review will discuss the historical timeline of radioimmunotherapy, debate on advantages and difficulties, and explore trials. We will examine future directions of radioligand therapy in hemato-oncology, considering emerging molecules that may become the next theragnostic trend.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Biomarker, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: What prognostic factors have impacted the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic oral cancer? (Pubmed Central) - Aug 31, 2024 Our findings imply that the use of antibiotics and PPIs, which can modify the gut microbiota, may also serve as a prognostic determinant for ICI treatment in RM-OC, consistent with previous studies. Additionally, PNI may be essential in affecting the survival rates of both PFS and OS and could be an exceedingly valuable inflammatory biomarker for RM-OC.
- |||||||||| Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis, Yervoy (ipilimumab) / BMS
P1 data, Journal, Metastases: Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. (Pubmed Central) - Aug 31, 2024 P1 Additionally, PNI may be essential in affecting the survival rates of both PFS and OS and could be an exceedingly valuable inflammatory biomarker for RM-OC. CaboNivo and CaboNivoIpi demonstrated clinical activity and safety in patients with multiple GU malignancies, especially clear cell RCC, urothelial carcinoma, and rare GU tumors such as squamous cell carcinoma of the bladder, small cell carcinoma of the bladder, adenocarcinoma of the bladder, renal medullary carcinoma, and penile cancer.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, Monotherapy, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ? 50% Advanced NSCLC. (Pubmed Central) - Aug 31, 2024 With 5-year follow-up in a real-world population, frontline pembrolizumab monotherapy continues to demonstrate long-term effectiveness, with survival outcomes consistent with those of pivotal clinical trials, for treating patients with advanced NSCLC with PD-L1 expression of ? 50% and no EGFR, ALK, or ROS1 genomic alteration.
|